Although initial chemotherapy eliminated the dominant Group B tumor population, a therapy-resistant Group A subclone with enhanced metabolic activity, EMT features, and PI3K–mTOR–EIF4EBP1 signaling emerged, driving relapse. The gene discussed is MTOR; the disease is neoplasm.